Adatanserin (WY-50324 SEB-324) is a mixed 5-HT1A receptor partial agonist and 5-HT2A and 5-HT2C receptor antagonist. It was under development by Wyeth as an antidepressant but was ultimately shelved.Adantaserin has been shown to be neuroprotective against ischemia-induced glutamatergic excitotoxicity an effect which appears to be mediated by blockade of the 5-HT2A receptor.
This page contains content from the copyrighted Wikipedia article "Adatanserin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
